CURE

FDA Grants Designation to Investigational Drug for Head and Neck Cancer

The FDA has granted fast track designation to the investigational drug CRB-701 for recurrent or metastatic head and neck ...

FDA Grants Fast Track Designation to Corbus Pharmaceuticals’ Nectin-4 Targeting ADC CRB-701 in Head and Neck Squamous Cell Carcinoma

Dose optimization data from the Phase 1/2 study to be presented next month at ESMO 2025Second Fast Track designation granted ...
Targeted Oncology

Novel ADC Earns FDA Fast Track in Head and Neck Cancer

The FDA has granted fast track designation to the antibody-drug conjugate (ADC) CRB-701 for the treatment of recurrent or ...

Corbus Gets FDA Fast Track Designation for Cancer Drug

Corbus Pharmaceuticals received fast track designation from the FDA for CRB-701, a drug to be used in the treatment of head and neck squamous cell carcinoma, a kind of cancer. A continuing clinical ...
abc27

Corbus Pharmaceuticals Presents New CRB-913 Pre-Clinical Data At Obesity Week 2024

CRB-913 brain levels are 15-fold lower than monlunabant in lean mice Dose-response demonstrated for a range of 5 to 80 mg/kg/day achieving up to 38% weight loss in DIO mice Semaglutide treatment ...